Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: a real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).

Zdravko MitrovicDino DujmovicOzren JaksicSandra Basic KindaPetar GacinaVlatka PerisaZeljko PrkaBarbara DretaDavor GalusicHrvoje HolikVlatko PejsaIgor Aurer

Published in: European journal of haematology (2023)

DA-EPOCH-R is efficacious in sufficiently fit older high-risk DLBCL patients. Patients with poor PS have unacceptable toxicity and require less intensive therapy.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
physical activity
ejection fraction
newly diagnosed
chronic kidney disease
community dwelling
peritoneal dialysis
oxidative stress
patient reported outcomes
bone marrow
hodgkin lymphoma
replacement therapy